At least one drug maker sanctioned earlier this month by the European Commission for pay-for-delay agreements has appealed the sanction, according to reports.
Pharmaceutical firm Mylan, which owns Matrix laboratories – one of the companies fined by the Commission – will challenge the fines that were imposed after the Commission found Matrix to have struck anticompetitive agreements with France’s Servier Laboratories to delay Matrix’s generic, cheaper form of a competing drug.
Five companies in total were fined by the Commission. Lupin and Unichem, also fined, also vowed to appeal the ruling.
Full content: Hindu Business Line
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.